KLK3 and benign prostatic hyperplasia: Data from the placebo arm of the MTOPS trial demonstrated that men with a total PV ≥ 31 ml, PSA ≥ 1.6 ng/ml, Qmax < 10.6 ml/s, PVR volume ≥ 39 ml or age ≥ 62 years at baseline had a significantly increased risk of overall clinical progression of BPH (20).